UFT Plus Leucovorin for Metastatic Colorectal Cancer: Japanese Experience
ByWataru Ichikawa, MD, PhD,Zenro Nihei, MD, PhD,Hiroyuki Uetake, MD,Hiroyuki Yamada, MD,Yoshinori Shirota, MD,Kenichi Sugihara, MD, PhD
Published: | Updated:
In the United States and Europe, the combination of oral UFT plus leucovorin has been reported to produce objective responses and survival rates similar to those achieved with standard intravenous 5-fluorouracil plus leucovorin in patients with metastatic colorectal cancer, with reduced toxicity.